AstraZeneca Advances Drug Pipeline as UAE Approves Etcamah for Dermatitis

AstraZeneca has identified five high-potential candidates to lead its late-stage clinical pipeline as the UAE Ministry of Health and Prevention (MoHAP) grants regulatory approval for the dermatitis treatment Etcamah. The pharmaceutical company is currently prioritizing these assets to meet a long-term revenue target of $80 billion by 2030. Pipeline Progress and Clinical Data Among the key developments is elecoglipron, an investigational oral GLP-1 receptor agonist. Recent clinical data indicates the drug is performing strongly in trials for weight management and type 2 diabetes. Unlike injectable treatments currently dominating the market, elecoglipron is a daily pill, which may improve patient adherence and reduce logistics costs for health providers. The company confirmed it is advancing five specific drugs into late-stage trials, focusing on oncology, rare diseases, and biopharmaceuticals. These candidates are expected to generate significant clinical data over the next 12 to 24 months, determining their path to global regulatory filings. UAE Regulatory Approval for Etcamah In a separate regulatory update, the UAE has authorized Etcamah (tralokinumab) for the treatment of…